---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-352346"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2026-08-14T20:21:11+00:00"
generated_at: "2026-08-14T20:29:29.419341+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cerenome (fka Plus Therapeutics) reports Q2 2026 net loss $9.0M, rebrands to CNSY

## Summary
- Q2 2026 net loss $9.0M ($1.31/sh) vs net income $5.2M ($0.62/sh) in Q2 2025, which included $6.5M derivative gain.
- Operating loss widened to $9.1M from $1.5M; grant revenue fell to $0.4M from $1.4M; cash flat at $8.6M.
- Rebranded from Plus Therapeutics to Cerenome on Aug 3, 2026; now trades as CNSY on Nasdaq.
- ReSPECT-GBM Phase 2 enrollment on track for 2026; data expected Q1 2027; ReSPECT-PBC first dosing Q3 2026.
- CNSide performed 232 tests in H1 2026; achieved 150M covered lives, CAP accreditation, and new partnerships.

## SEC filing metadata
- accession: 0001193125-26-352346
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2026-08-14T20:21:11+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000119312526352346/0001193125-26-352346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000119312526352346/pstv-20260814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-352346
- JSON: https://secwatch.observer/filing/0001193125-26-352346.json
- Plain text: https://secwatch.observer/filing/0001193125-26-352346.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.